The Mounjaro Drug Explained: Mechanism, Evidence and Real-World Use

The biggest misconception about Mounjaro: it is not simply 'a stronger Ozempic'

Most people arriving at this question already have a rough idea: they've heard of Ozempic, they know Mounjaro is newer, and somewhere they've picked up the impression that it's essentially the same drug with a bigger effect. That framing isn't quite right, and understanding why matters if you're trying to make a genuinely informed decision.

Ozempic contains semaglutide, a GLP-1 receptor agonist, it mimics one gut hormone. Mounjaro contains tirzepatide, which mimics two: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP receptors influence fat storage and energy expenditure through pathways that GLP-1 agonists don't reach. The practical result is a different and, in trials, larger average weight reduction. The SURMOUNT-5 head-to-head study, published in the New England Journal of Medicine in 2025, found tirzepatide produced greater average weight loss than semaglutide 2.4 mg over 72 weeks in adults with obesity who did not have diabetes. So it's not just a dose question, the underlying mechanism is meaningfully different.

It's also worth letting go of the idea that Mounjaro is a quick fix. Every clinical trial ran for at least 68 weeks alongside reduced-calorie eating and increased activity. The drug works within a structured programme, not instead of one. Our Mounjaro treatment page covers what that support looks like in practice.

What drug is in Mounjaro and how does it reduce body weight

The active substance is tirzepatide, a synthetic peptide engineered to bind both GIP and GLP-1 receptors at once. After a weekly subcutaneous injection (into the abdomen, thigh or upper arm, rotated each week), tirzepatide slows gastric emptying, reduces appetite signals in the brain and increases the sensation of fullness after eating. Insulin secretion rises when blood glucose is high; glucagon is suppressed. The cumulative effect is that people eat less without the conscious effort that calorie restriction normally demands.

Tirzepatide's drug class is sometimes listed as a 'dual GIP/GLP-1 receptor agonist' or, in earlier literature, a 'twincretin'. The NHS medicines page for tirzepatide describes this dual action and is the most accessible plain-language account of the pharmacology for UK readers.

The 2.5 mg starting dose exists to let your system adjust before the therapeutic range begins, some nausea or digestive discomfort is common early on, and starting low reduces that. The prescriber then titrates upward based on response and tolerability, not on a fixed calendar. How Mounjaro got its name and licence explains the regulatory journey from trial to UK approval.

Who the drug is licensed for (and what that means for you

The UK licence covers adults with a body mass index of 30 or above, or 27 and above where at least one weight-related condition is present) for example high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance, reflecting population differences in risk at lower BMI values.

NICE's appraisal of tirzepatide, TA1026, recommends it within the NHS for adults with a BMI of 35 or above plus at least one weight-related comorbidity, though NHS access is being phased in gradually. Private treatment through a regulated pharmacy is available to a broader group who meet the SmPC criteria, subject to a full clinical assessment. That assessment matters: the licence thresholds are starting points, not automatic approvals. The prescriber reviews your full health picture before deciding whether tirzepatide is appropriate for you specifically.

People who are pregnant, breastfeeding or actively trying to conceive should not take Mounjaro, it is not licensed for use in those situations. The drug is also not licensed for anyone under 18. A history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 requires particular caution and frank discussion with a prescriber. For a fuller look at how this drug sits alongside other weight-loss options, our weight-loss treatment overview lays out the landscape.

Side effects and what to watch for

The side-effect profile of tirzepatide is dominated by gastrointestinal symptoms: nausea, loose stools, constipation, indigestion and burping are the most reported. These tend to be most noticeable when starting or stepping up to the next dose, and they usually ease within a week or two as the body adapts. Fatigue, headache and mild dizziness appear less frequently.

A small number of people experience more serious effects that need prompt attention. The MHRA highlighted acute pancreatitis as a known, infrequent but potentially serious risk in a Drug Safety Update issued in January 2026: severe, persistent stomach pain that spreads to the back, with or without vomiting, warrants same-day medical contact. Gallbladder problems, significant dehydration from prolonged vomiting or diarrhoea, and allergic reactions are also listed in the prescribing information.

Mounjaro's Black Triangle status means the MHRA wants all suspected side effects reported. Patients can do this directly at yellowcard.mhra.gov.uk. If you've read about the cost of treatment and want to understand what a clinical service actually provides, our cost and value guide addresses that plainly.

If you'd like a prescriber to review your situation, speak to our prescribers via a free consultation, reviewed the same day by a GPhC-registered Independent Prescriber, with no obligation to proceed.